Related Experiment Videos
[Other antiarrhythmic agents]
12nd Department of Internal Medicine, Teikyo University School of Medicine.
Insights
This paper reviews recent advances in Digitalis for atrial fibrillation, ATP for paroxysmal supraventricular tachycardia, and enalapril for reducing sudden cardiac death in heart failure patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Digitalis effectively manages chronic atrial fibrillation (AF) ventricular rates.
- Atrial flutter and paroxysmal supraventricular tachycardia (PSVT) also benefit from Digitalis.
- Adenosine triphosphate (ATP) is a primary choice for rapid PSVT termination.
Purpose of the Study:
- To describe recent advancements in the therapeutic applications of Digitalis, ATP, and enalapril.
- To highlight the role of these drugs in managing cardiac arrhythmias and heart failure.
Main Methods:
- Review of recent literature and clinical findings regarding Digitalis, ATP, and enalapril.
- Analysis of data from studies like V-HeFT II concerning enalapril's impact on mortality.
Main Results:
- Digitalis is established for controlling ventricular rates in chronic AF, atrial flutter, and PSVT.
- ATP is a first-line treatment for the acute termination of PSVT.
- Enalapril demonstrated reduced mortality in V-HeFT II, likely by decreasing ventricular arrhythmias and increasing cardiac refractoriness.
Conclusions:
- Recent research supports the continued utility of Digitalis, ATP, and enalapril in cardiovascular medicine.
- These drugs offer distinct yet vital roles in managing arrhythmias and improving outcomes in heart failure patients.
Abstract:
Digitalis decreases the ventricular rates of chronic atrial fibrillation (AF), and is useful in the treatment of patients with AF. Furthermore it is used for atrial flutter and paroxysmal supraventricular tachycardia (PSVT). ATP has been used as a drug of first choice for quick termination of PSVT. In V-HeFT II, the lower mortality in the enalapril arm was attributable to reduction in the incidence of sudden death, probably due to ventricular arrhythmias. Besides, enalapril experimentally increases cardiac refractoriness. In this paper, recent advances in these three drugs are described.